AKT1 and acute myeloid leukemia: Sirolimus targets the serine/threonine-protein kinase: mammalian target of rapamycin (mTOR), and GA has been associated with the Akt/mTOR signaling pathway, demonstrating antileukemic efficacy in acute myeloid leukemia (AML) [38].